Skip to main content
TipRanks
Go Ultimate75% OFF

Adicet Bio (ACET) AI Stock Analysis

948 Followers
ACET

Adicet Bio

(NASDAQ:ACET)

Select Model
Rating:42Neutral
Price Target:$3.00â–²(7.91% Upside)
Action:reiterated
Date:11/06/26

The score is held down primarily by weak financial performance (no revenue, large losses, and significant cash burn) and very bearish technicals (price far below major moving averages with negative momentum). Offsetting these, corporate events provide some support via positive clinical/regulatory progress and upcoming pipeline catalysts, but valuation is not supportive given continued unprofitability and no dividend.

Positive Factors
Low LeverageLow leverage limits the balance-sheet burden while Adicet advances its clinical pipeline. Compared with a highly indebted development-stage biotech, this provides greater financial flexibility to fund trials and manage obligations, although it does not eliminate the need for future financing.
Negative Factors
No Current RevenueThe absence of current product revenue means Adicet has no commercial operating base to fund research and clinical development. Its ability to progress programs therefore remains dependent on financing, collaborations or future milestones, increasing execution sensitivity before any therapy reaches the market.

Adicet Bio (ACET) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%ACET-69.90%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$26.03M
Dividend Yield
―
Average Volume (3M)
233.09K
Price to Earnings (P/E)
-0.3
Beta (1Y)
1.92
Revenue Growth
―
EPS Growth
57.60%
Country
US
Employees
102
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Adicet Bio Business Overview & Revenue Model

Company Description

Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen recepto...

How the Company Makes Money

Adicet Bio does not have publicly established, recurring product revenue from marketed drugs (null for product sales), because it is a clinical-stage biotechnology company without approved commercial products. The company’s funding and revenue, when...

Adicet Bio Financial Statement Overview

Summary

Operating fundamentals are very weak: recent periods show $0 revenue, large ongoing net losses (about -$91.0M TTM), and persistent cash burn (operating cash flow about -$80.1M TTM; free cash flow about -$80.4M). The main offset is a relatively conservative balance sheet with low leverage (debt-to-equity ~0.12), though the equity base has shrunk materially over time.

Income Statement

18Very Negative

Balance Sheet

58Neutral

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000024.99M9.73M
Gross Profit-1.34M-6.38M0024.99M9.73M
EBITDA-85.04M-110.39M-110.65M-136.53M-67.04M-60.41M
Net Income-91.00M-116.80M-117.12M-142.66M-69.79M-62.00M
Balance Sheet
Total Assets128.95M192.35M220.22M207.29M330.69M338.94M
Cash, Cash Equivalents and Short-Term Investments100.94M158.53M176.30M159.71M257.66M277.54M
Total Debt12.10M14.74M17.23M20.92M21.02M20.94M
Total Liabilities26.25M33.15M33.61M37.12M38.35M35.81M
Stockholders Equity102.70M159.21M186.61M170.18M292.34M303.13M
Cash Flow
Free Cash Flow-80.43M-96.98M-93.50M-98.18M-61.55M-64.10M
Operating Cash Flow-80.14M-95.25M-92.38M-93.72M-44.77M-51.05M
Investing Cash Flow2.60M2.39M-119.24M-4.46M-16.78M-2.80M
Financing Cash Flow75.23M75.25M111.31M236.00K41.51M242.69M

Adicet Bio Technical Analysis

Technical Analysis SentimentNegative
Last Price2.78

Price Trends

50DMA5.93Negative
100DMA7.31Negative
200DMA7.43Negative

Market Momentum

MACD-0.83Negative
RSI17.54Positive
STOCH12.46Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACET, the sentiment is Negative. The current price of 2.78 is below the 20-day moving average (MA) of 3.52, below the 50-day MA of 5.93, and below the 200-day MA of 7.43, indicating a bearish trend. The MACD of -0.83 indicates Negative momentum. The RSI at 17.54 is Positive, neither overbought nor oversold. The STOCH value of 12.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACET.

Adicet Bio Risk Analysis

Adicet Bio disclosed 24 risk factors in its most recent earnings report. Adicet Bio reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Risks Related to Ownership of Our Common StockQ4, 2025
2.General Risk FactorsQ4, 2025
3.Risks Related to Our Internal Controls and Financial ReportingQ4, 2025

Adicet Bio Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ACET against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IMMXIMMX51Neutral$657.09M-9.45-24.93%――-5.65%
ACETACET42Neutral$26.03M-0.32-69.71%――57.60%
STROSTRO42Neutral$163.03M-0.78142.71%―-57.30%51.45%
GANXGANX41Neutral$46.31M-2.48-133.17%――33.17%
PMVPPMVP41Neutral$95.93M-0.82-110.22%――3.11%
ARTVARTV40Underperform$198.22M-1.34-45.32%――7.78%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%ACETSTROPMVPGANXIMMXARTVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ACET and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ACETAdicet Bio Inc2.78-6.84-71.10%
STROSutro Biopharma9.820.9210.34%
PMVPPmv Pharmaceuticals, Inc.1.27-0.13-9.29%
GANXGain Therapeutics, Inc.1.04-1.81-63.51%
IMMXImmix Biopharma, Inc.7.843.5984.47%
ARTVArtiva Biotherapeutics, Inc.4.010.123.08%

Adicet Bio Corporate Events

Business Operations and StrategyProduct-Related Announcements

Adicet Bio Advances Prula-cel Toward Pivotal Lupus Trial

Positive
Sep 28, 2026

On September 28, 2026, Adicet Bio reported Phase 1 data for its investigational therapy prula-cel in 22 patients with systemic lupus erythematosus, including 16 with lupus nephritis, with follow-up ranging from six to 21 months. At 12 months, 50% of...

Business Operations and StrategyProduct-Related Announcements

Adicet Bio Highlights Prula-cel Autoimmune CAR-T Pipeline Progress

Positive
Sep 8, 2026

On September 8, 2026, Adicet Bio posted an investor presentation outlining progress and key milestones across its pipeline of allogeneic gamma-delta1 CAR-T and in vivo CAR-T therapies, emphasizing prula-cel as a potential first off-the-shelf, one-tim...

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

Adicet Bio completes prula-cel Phase 1 SLE analysis

Positive
Sep 1, 2026

On September 1, 2026, Adicet Bio reported completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in systemic lupus erythematosus patients, with or without lupus nephritis, with t...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026